文献速递创伤与烧伤消化、代谢与肾脏急症

瑞士滑雪场第一响应者使用鼻内纳布啡对院前创伤患者镇痛:一项观察性队列研究

Nasal nalbuphine analgesia in prehospital trauma managed by first-responder personnel on ski slopes in Switzerland: an observational cohort study.
PubMed 文献 · Scand J Trauma Resusc Emerg Med · 2021-02-17
一句话结论在瑞士6个滑雪场,第一响应者按严格流程给予鼻内纳布啡,可使创伤患者疼痛评分中位数从8分平均降低3分(p<0.001),未观察到重大副作用。

该观察性队列研究纳入瑞士6个滑雪场中由第一响应者使用鼻内纳布啡镇痛的267例创伤患者,第一响应者均被指导先评估使用纳布啡镇痛的可行性,并依据制定的治疗流程严格给药。结果显示鼻内纳布啡可有效缓解疼痛,疼痛数字评分中位数平均降低3分,从8分降至(原文未给出终点具体数值)水平(p<0.001);多因素回归模型显示初始疼痛评分较高的患者疼痛缓解更明显,青少年患者的镇痛效果优于20至60岁患者(p=0.006),未观察到重大副作用。作者认为,第一响应者经鼻给予纳布啡是一种可能安全有效的无创镇痛策略,尤其适用于严重疼痛且第一响应者到达至EMS/HEMS人员到达现场间隔较长时。

要点

  • 267例滑雪场创伤患者由第一响应者按严格流程给予鼻内纳布啡,疼痛数字评分中位数平均降低3分(p<0.001)。
  • 多因素回归模型显示,初始疼痛评分越高的患者,鼻内纳布啡的疼痛缓解越明显。
  • 青少年患者鼻内纳布啡的镇痛效果优于20至60岁患者(p=0.006)。
  • 研究中未观察到重大副作用。
  • 作者认为,鼻内纳布啡尤其适用于严重疼痛且第一响应者至EMS/HEMS到达间隔较长时。

适用人群与场景

  • 瑞士6个滑雪场中由第一响应者处置的创伤患者,共267例纳入分析。
  • 适用范围为第一响应者到达后、EMS/HEMS人员到达现场前的院前阶段。

诊断标准与关键阈值

  • 第一响应者开始治疗前需先评估使用纳布啡治疗该患者疼痛的可行性。
  • 研究制定了治疗流程并分发给第一响应者,以确保纳布啡仅按严格流程给药。

处置流程与药物剂量

  • 第一响应者按研究制定的治疗流程给予鼻内纳布啡镇痛,具体剂量原文未写明。
  • 数据收集:现场记录给药前后疼痛评分及疼痛缓解情况;第一响应者在交回完整问卷时领取补充药品。

研究设计与关键结果

  • 观察性队列研究,纳入瑞士6个滑雪场中由第一响应者使用鼻内纳布啡镇痛的267例创伤患者。
  • 疼痛数字评分中位数平均降低3分,从8分下降(p<0.001)。
  • 多因素回归模型显示,初始疼痛评分较高的患者疼痛缓解更明显。
  • 鼻内纳布啡在青少年中的镇痛效果优于20至60岁患者(p=0.006)。
  • 未观察到重大副作用。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,第一响应者经鼻给予纳布啡是一种可能安全有效的无创镇痛策略,适用于院前急性创伤患者。
  • 作者认为,在严重疼痛且第一响应者到达至EMS/HEMS人员到达现场间隔较长时,鼻内纳布啡可能是一种替代选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pain is one of the major symptoms complained about by patients in the prehospital setting, especially in the case of trauma. When there is mountainous topography, as in Switzerland, there may be a time delay between injury and arrival of professional rescuers, in particular on ski slopes. Administration of a safe opioid by first responders may improve overall treatment. We therefore assessed administration of nasal nalbuphine as an analgesic treatment for trauma patients in Switzerland.

METHODS: This observational cohort study examined 267 patients who were treated with nasal nalbuphine by first responders in six ski resorts in Switzerland. All first responders were instructed to begin treatment by assessing the feasibility of using nalbuphine to treat pain in the patient. A treatment algorithm was developed and distributed to assure that nalbuphine was only administered following a strict protocol. Data regarding pain scores and pain reduction after administration of nalbuphine were collected on-site. Refills were handed out to the first responders with the return of each completed questionnaire.

RESULTS: Nalbuphine provided effective pain relief, with the median level of pain on the numeric rating scale for pain reduced by 3 units on average, from 8 points (p < 0.001). The multivariate regression model showed that pain reduction was more pronounced in patients with higher initial pain levels. Nalbuphine was more effective in adolsecents than in patients aged 20 to 60 years (p = 0.006). No major side effects were observed.

CONCLUSION: Nasal administration of nalbuphine by first responders is a presumably safe and effective noninvasive pain management strategy for acutely injured patients in the prehospital setting. This may be an alternative, especially in the case of severe pain and prolonged time between arrival of the first responders and arrival of EMS/HEMS personnel on scene.

来源:Scand J Trauma Resusc Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Pietsch U, Berger Y, Schurter D, et al. Nasal nalbuphine analgesia in prehospital trauma managed by first-responder personnel on ski slopes in Switzerland: an observational cohort study. Scand J Trauma Resusc Emerg Med. 2021. PMID: 33596970. doi:10.1186/s13049-021-00852-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。